Xiubao Ren

机构：National Medical Products Administration, Tianjin Medical University Cancer Institute and Hospital · ORCID：0000-0003-4137-2049

发表论文 453 篇 · 总被引 15305 次 · h-index 62

代表论文

• Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma (2024 · Experimental Hematology and Oncology · 被引 15)
• Fecal microbiota transplantation alleviates cirrhotic portal hypertension in rats via butyrate-mediated HDAC3 inhibition and PI3K/Akt/eNOS signaling regulation (2025 · European Journal of Pharmacology · 被引 12)
• First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial (2025 · The Lancet Oncology · 被引 10)
• CK2B Induces CD8 + T‐Cell Exhaustion through HDAC8‐Mediated Epigenetic Reprogramming to Limit the Efficacy of Anti‐PD‐1 Therapy in Non‐Small‐Cell Lung Cancer (2025 · Advanced Science · 被引 10)
• A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib (2025 · Signal Transduction and Targeted Therapy · 被引 8)
• First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 7)